Nervgen Pharma (NGEN) Exchange Rate Effect (2025 - 2026)
Nervgen Pharma's (NGEN) quarterly Exchange Rate Effect came in at -$1.6 million in Q2 2026, down 2512.09% year-over-year from $65429.7 in Q2 2025, and down 2086.32% quarter-over-quarter from -$72186.3 in Q1 2026.
Powered by 
Analysis
Nervgen Pharma (NGEN) Exchange Rate Effect (2025 - 2026) Analysis & Trends
Nervgen Pharma (NGEN) has reported Exchange Rate Effect for 2 consecutive years, with -$1.6 million the latest figure, recorded in Q2 2026.
- On a quarterly basis, Exchange Rate Effect fell 2512.09% year-over-year to -$1.6 million in Q2 2026; TTM through Jun 2026 was -$1.6 million, a N/A change from a year earlier, with the FY2025 full-year figure at $313003.9, up 240.5% from the prior year.
- Exchange Rate Effect was -$1.6 million for Q2 2026 at Nervgen Pharma, down from -$72186.3 in the prior quarter.
- Over five years, Exchange Rate Effect peaked at $65429.7 in Q2 2025 and troughed at -$1.6 million in Q2 2026.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Exchange Rate Effect (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 207.01 Bn | 193.02 Bn | 7.24 Bn | - |
| 2 | Gilead Sciences | 179.98 Bn | 176.80 Bn | 6.22 Bn | -19.00 Mn |
| 3 | Vertex Pharmaceuticals | 131.45 Bn | 123.60 Bn | 2.84 Bn | -3.70 Mn |
| 4 | Regeneron Pharmaceuticals | 82.02 Bn | 74.03 Bn | 3.93 Bn | -300,000.00 |
| 5 | Argenx Se | 60.35 Bn | 55.16 Bn | 1.37 Bn | - |
| 6 | Moderna | 53.69 Bn | 48.55 Bn | 52.00 Mn | -2.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.11 Bn | 29.80 Bn | 992.69 Mn | -2.45 Mn |
| 8 | Biogen | 31.93 Bn | 30.64 Bn | 1.96 Bn | -3.40 Mn |
| 9 | Roivant Sciences | 29.21 Bn | 29.21 Bn | 1.16 Mn | 315,000.00 |
| 10 | Nervgen Pharma | 152.98 Mn | 152.98 Mn | - | -1.58 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -1.58 Mn |
| Mar 31, 2026 | -72,186.26 |
| Jun 30, 2025 | 65,429.73 |
| Mar 31, 2025 | 15,948.24 |